Skip to main content
Belinda Akpa applies her diverse expertise and high-performance computing to accelerate the drug discovery process and increase the chances of success when candidate molecules go to clinical trials. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.

Heavy-duty vehicles contribute 23% of transportation emissions of greenhouse gases and account for almost one-quarter of the fuel consumed annually in the U.S. Credit: Chris Bair/Unsplash

Through a consortium of Department of Energy national laboratories, ORNL scientists are applying their expertise to provide solutions that enable the commercialization of emission-free hydrogen fuel cell technology for heavy-duty

Nuclear engineer Nesrin Ozgan Cetiner led ORNL’s collaboration with AMS Corp. to test instrument and control sensors for the next generation of nuclear power reactor technology. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Toward the goal of bringing the next generation of nuclear power reactor technology online this decade, ORNL and Analysis and Measurement Services Corporation have successfully completed loop testing of instrument and control sensors for an advanced reactor design for small modular reactors.

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

ATOM logo

The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.

Targeted alpha therapy can deliver radiation to specific cells, with minimal effect on surrounding, healthy cells. Credit: Michelle Lehman and Jaimee Janiga/ORNL, U.S. Dept. of Energy

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.

Neutron scattering experiments show electric charges, shown in red, blue and grey, in the SARS-CoV-2 main protease site where telaprevir binds to the structure. The experiments provide critical data for the design of small-molecule drugs to treat COVID-19. Credit: Jill Hemman and Michelle Lehman/ORNL, U.S. Dept. of Energy

Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.  

ORNL researchers combined additive manufacturing with conventional compression molding to produce high-performance thermoplastic composites, demonstrating the potential for the use of large-scale multimaterial preforms to create molded composites. Credit: ORNL/U.S. Dept. of Energy

Oak Ridge National Laboratory researchers combined additive manufacturing with conventional compression molding to produce high-performance thermoplastic composites reinforced with short carbon fibers.

Researchers at ORNL and the University of Tennessee developed an automated workflow that combines chemical robotics and machine learning to speed the search for stable perovskites. Credit: Jaimee Janiga/ORNL, U.S. Dept of Energy

Researchers at the Department of Energy’s Oak Ridge National Laboratory and the University of Tennessee are automating the search for new materials to advance solar energy technologies.

ORNL researchers are developing a method to print low-cost, high-fidelity, customizable sensors for monitoring power grid equipment. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

A method developed at Oak Ridge National Laboratory to print high-fidelity, passive sensors for energy applications can reduce the cost of monitoring critical power grid assets.